Skip to main content
 

Investors & Media

Corporate Profile
At WAVE Life Sciences, we are driven by an unwavering passion and commitment to deliver on our mission of confronting challenging diseases by developing transformational therapies and empowering patients. We are utilizing our innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare and other serious genetically defined diseases. Given the versatility of our chemistry platform, WAVE’s deep, diverse pipeline spans multiple modalities including antisense, exon-skipping, and single-stranded RNAi.
Recent News
August 9, 2017
Wave Life Sciences Reports Second Quarter 2017 Financial Results and Provides Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 9, 2017-- Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced financial results for the second quarter ended June 30, 2017. “We recently achieved two major milestones: transitioning to a clinical stage company, with the commencement of our two phase 1b/2a trials in Hunt... 
July 17, 2017
Wave Life Sciences Initiates Two Phase 1b/2a Clinical Trials: PRECISION-HD1 and PRECISION-HD2 in Patients with Huntington’s Disease
Trials Evaluate the First Allele-Specific Investigational Drugs for Huntington’s Disease, WVE-120101 and WVE-120102 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 17, 2017-- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced the initiation of the Company’s PRECISION-HD program, which includes PRECISION-HD1 and ... 
June 8, 2017
ReadCoor and WAVE Life Sciences Initiate Research Collaboration
Collaboration aims to unlock next generation stereopure nucleic acid targets with novel FISSEQ technologies CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 8, 2017-- ReadCoor, Inc., a company reinventing omics and pathology with its panomic spatial sequencing platform, and WAVE Life Sciences Ltd. (NASDAQ:WVE), a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, today announced the initia... 

view all

Upcoming Events
There are currently no events scheduled.

view all